Výsledky vyhledávání

Akademický článek

Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials.

Autor: Ze-Chun Zhang, Qi-Ni Xu, Sui-Ling Lin, Xu-Yuan Li

Publikováno v: PLoS ONE, Vol 11, Iss 10, p e0164663 (2016)

Capecitabine has been investigated in early breast cancer in several studies, but it was undefined that whether it could improve survival. To investigate whether the addition of capecitabine affected survival in patients with early breast cancer, a m

Externí odkaz: https://doaj.org/article/78c80f8dfd584982ad1f5a9f51660a8b

Zobrazit plný text záznamu

Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials

Autor: Xuyuan Li, Qi-Ni Xu, Wen-zhao Lin, Hong-biao Wang

Publikováno v: Breast Cancer. 24:345-352

To compare the addition of targeted agents to fulvestrant with fulvestrant alone in hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy; a meta-analysis of all relevant randomized controlled trials was performed.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ac00cde6bb4a4818a7169054f97ea1e
https://doi.org/10.1007/s12282-017-0770-3

Zobrazit plný text záznamu

Effect of consolidation chemotherapy following definitive chemoradiotherapy in patients with esophageal squamous cell cancer

Autor: Ze-Sen Du, Zhi-Yong Wu, Hong-Yao Xu, He-San Luo, Sheng-Xi Wu, Qi-Ni Xu, He-Cheng Huang, Xu-Yuan Li

Publikováno v: Scientific Reports
Scientific Reports, Vol 7, Iss 1, Pp 1-5 (2017)

Definitive chemoradiotherapy (dCRT) is a treatment option for patients with localized esophageal squamous cell carcinoma (ESCC). We investigated consolidation chemotherapy (CCT) in patients with ESCC who attained clinical complete response after dCRT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6c7d9dc17f0b4fdb185a42637ad66e9
http://europepmc.org/articles/PMC5715009

Zobrazit plný text záznamu

Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials

Autor: Qi-Ni Xu, Wen-zhao Lin, Xuyuan Li, Hong-biao Wang

Publikováno v: Current Medical Research and Opinion. 30:2295-2304

To compare the effects of adding targeted agents to standard second-line chemotherapy with a single agent (pemetrexed or docetaxel) in patients with advanced NSCLC, a meta-analysis of all relevant randomized controlled trials was performed and overal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9667ad4057c55f431ffc0c47647ae84f
https://doi.org/10.1185/03007995.2014.909392

Zobrazit plný text záznamu

CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer

Autor: Hong-Wei Huang, Jia-Zhou Lin, Qi-Ni Xu, Li-Sheng Huang, Hong-biao Wang, Xu-Yuan Li

Publikováno v: Medicine. 98:e13909

Background Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (palbociclib and abemaciclib) and mammalian target of rapamycin (mTOR) inhibitors (everolimus) are effective agents for restoring endocrine sensitivity in patients with advanced breast cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3d89e642f13be05ad6dde753b6b0c34d
https://doi.org/10.1097/md.0000000000013909

Zobrazit plný text záznamu

Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials

Autor: Qi-Ni Xu, Haoquan Cai, Shuhan Yu, Yun Yuan, Xuyuan Li

Publikováno v: Current medical research and opinion. 32(12)

To compare the effects of an erlotinib-based targeted dual agent with erlotinib alone in previously treated patients with advanced non-small lung cancer (NSCLC).The PubMed and Embase databases and the Cochrane Central Register of Controlled Trials we

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f233e44686f6d9ae95ec3056ace74f85
https://pubmed.ncbi.nlm.nih.gov/27479336

Zobrazit plný text záznamu